Home › RLT targets by cancer › Prostate Cancer
Radioligand therapy · Prostate Cancer

Radioligand Therapy Targets in Prostate Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in prostate cancer (including metastatic castration-resistant prostate cancer (mCRPC)). 4,139 show detectable protein staining. Established and emerging radioligand targets expressed in prostate cancer include PSMA (FOLH1), EPCAM, B7-H3 (CD276) and HER3 (ERBB3). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Prostate cancer is where radioligand therapy has its biggest clinical success: PSMA-targeted 177Lu-vipivotide tetraxetan (Pluvicto) is FDA-approved for mCRPC. The race now is for targets beyond PSMA, for PSMA-low disease and for combination strategies. See our guide to radioligand targets for PSMA-low and PSMA-negative prostate cancer.

Need a shortlist for your own prostate cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank prostate cancer targets free

Established and emerging radioligand targets in prostate cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in prostate cancer:

TargetIHC in prostate cancer% positiveInternalizes
PSMA (FOLH1)High (1.00)100%yes
EPCAMHigh (0.94)100%—
B7-H3 (CD276)High (0.75)100%—
HER3 (ERBB3)High (0.72)100%yes
STEAP2High (0.64)100%—
FAPHigh (0.53)90%yes
TMEFF2High (0.53)92%—
c-MET (MET)Medium (0.47)100%yes
ITGAVMedium (0.47)100%—
EGFRMedium (0.39)67%yes
Nectin-4 (NECTIN4)Low (0.15)46%no
CD38Low (0.11)17%—
SSTR2Low (0.08)17%yes
DLK1Low (0.06)18%—
CD19Low (0.06)9%—
STEAP1Low (0.04)11%—
CD45 (PTPRC)Low (0.03)8%no

Top cell-surface targets for prostate cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in prostate cancer% positiveInternalizesClinical stage
1PSMA (FOLH1)
folate hydrolase 1
High (1.00)100%yesFDA-Approved
2PTPRB
protein tyrosine phosphatase receptor type B
High (0.97)100%yesClinical
3CYSLTR2
cysteinyl leukotriene receptor 2
High (1.00)100%yesDiscovery
4IGF1R
insulin like growth factor 1 receptor
High (0.73)100%yesFDA-Approved
5HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.72)100%yesFDA-Approved
6AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
7MAOB
monoamine oxidase B
High (1.00)100%—FDA-Approved
8ADGRL1
adhesion G protein-coupled receptor L1
High (1.00)100%yesDiscovery
9AGTRAP
angiotensin II receptor associated protein
High (0.97)100%yesDiscovery
10FLT4
fms related receptor tyrosine kinase 4
High (0.56)92%yesFDA-Approved
11CHRM2
cholinergic receptor muscarinic 2
High (0.92)100%uncertainFDA-Approved
12NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.82)100%uncertainFDA-Approved
13FAAH
fatty acid amide hydrolase
High (0.88)100%—FDA-Approved
14GABRP
gamma-aminobutyric acid type A receptor subunit pi
High (0.94)100%uncertainFDA-Approved
15GPR139
G protein-coupled receptor 139
High (0.89)100%yesDiscovery
16c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
Medium (0.47)100%yesFDA-Approved
17NOTCH1
notch receptor 1
High (0.67)100%yesClinical
18EGFR
epidermal growth factor receptor
Medium (0.39)67%yesFDA-Approved
19M6PR
mannose-6-phosphate receptor, cation dependent
High (0.81)100%yesDiscovery
20BDKRB1
bradykinin receptor B1
High (0.97)100%uncertainClinical
21BRAF
B-Raf proto-oncogene, serine/threonine kinase
High (0.97)100%—FDA-Approved
22EPHB2
EPH receptor B2
High (0.61)100%uncertainFDA-Approved
23ACP3
acid phosphatase 3
High (1.00)100%—Discovery
24IL1R2
interleukin 1 receptor type 2
High (0.61)92%yesDiscovery
25HTR6
5-hydroxytryptamine receptor 6
Medium (0.41)100%yesFDA-Approved

Internalizing receptors in prostate cancer

Targets expressed in prostate cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

PSMA (FOLH1) · PTPRB · CYSLTR2 · IGF1R · HER3 (ERBB3) · AMFR · ADGRL1 · AGTRAP · FLT4 · GPR139 · c-MET (MET) · NOTCH1

Prostate Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in prostate cancer. Clinical precedent lowers development risk but usually means more competition:

PSMA (FOLH1) · PTPRB · IGF1R · HER3 (ERBB3) · MAOB · FLT4 · CHRM2 · NR3C2 · FAAH · GABRP · c-MET (MET) · NOTCH1

How these prostate cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in prostate cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank prostate cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free prostate cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist prostate cancer targets for your program · 5 free analyses, no card Rank prostate cancer targets free